Citadel Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Citadel Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,100	Closed	-$2.78M	–	15784
2025 Q1	$2.78M	Buy	21,100 +13,000	+160%	+$1.62M	﹤0.01%	4903
2024 Q4	$677K	Sell	8,100 -13,700	-63%	-$1.13M	﹤0.01%	7901
2024 Q3	$1.6M	Sell	21,800 -500	-2%	-$37.6K	﹤0.01%	5934
2024 Q2	$1.53M	Sell	22,300 -38,000	-63%	-$2.64M	﹤0.01%	5813
2024 Q1	$4.17M	Buy	60,300 +36,900	+158%	+$2.54M	﹤0.01%	4224
2023 Q4	$1.68M	Buy	23,400 +5,000	+27%	+$288K	﹤0.01%	5683
2023 Q3	$958K	Buy	18,400 +700	+4%	+$40.8K	﹤0.01%	6638
2023 Q2	$1.12M	Sell	17,700 -22,200	-56%	-$1.38M	﹤0.01%	6225
2023 Q1	$2.16M	Sell	39,900 -11,300	-22%	-$546K	﹤0.01%	5212
2022 Q4	$2.71M	Buy	51,200 +8,600	+20%	+$431K	﹤0.01%	4919
2022 Q3	$1.98M	Buy	42,600 +4,300	+11%	+$225K	﹤0.01%	5613
2022 Q2	$2.19M	Buy	38,300 +6,000	+19%	+$340K	﹤0.01%	5363
2022 Q1	$1.98M	Sell	32,300 -53,400	-62%	-$2.77M	﹤0.01%	6107
2021 Q4	$4.49M	Buy	85,700 +34,100	+66%	+$1.43M	﹤0.01%	4516
2021 Q3	$1.92M	Sell	51,600 -7,000	-12%	-$243K	﹤0.01%	6460
2021 Q2	$2.39M	Sell	58,600 -1,900	-3%	-$70.2K	﹤0.01%	6153
2021 Q1	$2.05M	Sell	60,500 -78,400	-56%	-$2.72M	﹤0.01%	6317
2020 Q4	$4.42M	Sell	138,900 -65,400	-32%	-$1.72M	﹤0.01%	3883
2020 Q3	$5.24M	Buy	204,300 +19,900	+11%	+$454K	﹤0.01%	3084
2020 Q2	$4.73M	Buy	184,400 +38,200	+26%	+$773K	﹤0.01%	3169
2020 Q1	$2.25M	Sell	146,200 -1,448,200	-91%	-$31.5M	﹤0.01%	3942
2019 Q4	$54.7M	Buy	1,594,400 +816,500	+105%	+$9.8M	0.02%	722
2019 Q3	$5.81M	Buy	777,900 +669,800	+620%	+$6.42M	﹤0.01%	2902
2019 Q2	$1.4M	Buy	108,100 +89,300	+475%	+$1.15M	﹤0.01%	5132
2019 Q1	$229K	Sell	18,800 -57,700	-75%	-$737K	﹤0.01%	8021
2018 Q4	$871K	Buy	76,500 +43,400	+131%	+$701K	﹤0.01%	5511
2018 Q3	$718K	Buy	33,100 +2,200	+7%	+$46K	﹤0.01%	6115
2018 Q2	$546K	Buy	30,900 +2,400	+8%	+$48.7K	﹤0.01%	6226
2018 Q1	$600K	Buy	28,500 +11,300	+66%	+$220K	﹤0.01%	5591
2017 Q4	$249K	Sell	17,200 -6,300	-27%	-$97.3K	﹤0.01%	6751
2017 Q3	$371K	Buy	23,500 +10,400	+79%	+$153K	﹤0.01%	5739
2017 Q2	$163K	Buy	13,100 +2,200	+20%	+$25.5K	﹤0.01%	6682
2017 Q1	$177K	Sell	10,900 -8,300	-43%	-$120K	﹤0.01%	6610
2016 Q4	$290K	Sell	19,200 -20,800	-52%	-$294K	﹤0.01%	5719
2016 Q3	$610K	Buy	40,000 +9,100	+29%	+$368K	﹤0.01%	4551
2016 Q2	$1.2M	Buy	30,900 +10,800	+54%	+$388K	﹤0.01%	3347
2016 Q1	$559K	Buy	20,100 +6,400	+47%	+$213K	﹤0.01%	4257
2015 Q4	$737K	Sell	13,700 -6,600	-33%	-$333K	﹤0.01%	3972
2015 Q3	$813K	Buy	20,300 +10,600	+109%	+$346K	﹤0.01%	4097
2015 Q2	$310K	Buy	+9,700	New	+$246K	﹤0.01%	5697

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's ITCI Position: Q2 2025 in Review

Citadel Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,237,131 shares — an estimated $295M sold.

Citadel Advisors first reported a position in ITCI in Q1 2015 and held it in 40 quarters. The position peaked at $295M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Citadel Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 2,237,131 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $295M.
Citadel Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 40 quarters.
Citadel Advisors's Intra-Cellular Therapies Inc. position peaked at $295M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.